VHCP Management III
Latest statistics and disclosures from VHCP Management III's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AXSM, Constellation Pharmceticls I, MIST, RLMD, ETNB, and represent 72.83% of VHCP Management III's stock portfolio.
- Added to shares of these 10 stocks: Constellation Pharmceticls I (+$115M), RLMD (+$30M), ETNB (+$25M), Forty Seven (+$20M), ITCI (+$20M), Iveric Bio (+$15M), Adverum Biotechnologies (+$11M), MRSN (+$8.9M), Myovant Sciences (+$7.1M), NXTC (+$6.7M).
- Started 9 new stock positions in Forty Seven, ETNB, ITCI, Myovant Sciences, MRSN, RLMD, Adverum Biotechnologies, NXTC, Iveric Bio.
- Reduced shares in these 10 stocks: Ra Pharmaceuticals (-$16M), La Jolla Pharmaceuticl Com Par (-$11M), , PTGX (-$7.0M), AXSM (-$6.5M), Tricida, Kiniksa Pharmaceuticals, Obseva Sa, Bellerophon Therapeutics, Radius Health.
- Sold out of its positions in BCRX, La Jolla Pharmaceuticl Com Par, Prevail Therapeutics Ord, Proteostasis Therapeutics In, Ra Pharmaceuticals, Radius Health, Tricida, Kiniksa Pharmaceuticals.
- VHCP Management III was a net buyer of stock by $208M.
- VHCP Management III has $504M in assets under management (AUM), dropping by 210.94%.
- Central Index Key (CIK): 0001738053
Tip: Access up to 7 years of quarterly data
Positions held by VHCP Management III consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VHCP Management III
VHCP Management III holds 18 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 31.8 | $160M | -3% | 1.5M | 103.36 |
|
| Constellation Pharmceticls I | 23.5 | $119M | +3674% | 2.5M | 47.11 |
|
| Milestone Pharmaceuticals (MIST) | 6.6 | $33M | 2.1M | 16.01 |
|
|
| Relmada Therapeutics (RLMD) | 6.0 | $30M | NEW | 768k | 39.00 |
|
| 89bio (ETNB) | 5.0 | $25M | NEW | 959k | 26.29 |
|
| 10x Genomics Inc Cl A (TXG) | 4.5 | $23M | 300k | 76.25 |
|
|
| Forty Seven | 4.0 | $20M | NEW | 516k | 39.37 |
|
| Intra Cellular Therapies (ITCI) | 3.9 | $20M | NEW | 575k | 34.31 |
|
| Iveric Bio | 2.9 | $15M | NEW | 1.7M | 8.58 |
|
| Kalvista Pharmaceuticals (KALV) | 2.2 | $11M | -2% | 620k | 17.81 |
|
| Adverum Biotechnologies | 2.2 | $11M | NEW | 946k | 11.52 |
|
| Marinus Pharmaceuticals | 2.1 | $11M | +99% | 5.0M | 2.16 |
|
| Mersana Therapeutics (MRSN) | 1.8 | $8.9M | NEW | 1.6M | 5.73 |
|
| Myovant Sciences | 1.4 | $7.1M | NEW | 455k | 15.52 |
|
| Nextcure (NXTC) | 1.3 | $6.7M | NEW | 120k | 56.33 |
|
| Obseva Sa | 0.6 | $3.1M | -30% | 810k | 3.82 |
|
| Protagonist Therapeutics (PTGX) | 0.1 | $571k | -92% | 81k | 7.06 |
|
| Bellerophon Therapeutics | 0.0 | $134k | -84% | 384k | 0.35 |
|
Past Filings by VHCP Management III
SEC 13F filings are viewable for VHCP Management III going back to 2018
- VHCP Management III 2019 Q4 filed Feb. 13, 2020
- VHCP Management III 2019 Q3 filed Nov. 13, 2019
- VHCP Management III 2019 Q2 filed Aug. 13, 2019
- VHCP Management III 2019 Q1 filed May 14, 2019
- VHCP Management III 2018 Q4 filed Feb. 13, 2019
- VHCP Management III 2018 Q3 filed Nov. 13, 2018